Roche has brought Evrysdi (risdiplam) to India ahead of rival spinal muscular atrophy (SMA) treatments Novartis AG’ Zolgensma (onasemnogene abeparvovec) and Biogen, Inc.’s Spinraza (nusinersen), backed by a patient support program (PSP) that could potentially soften the pricing blow for patients in a largely out-of-pocket market.
Evrysdi, the first and only oral SMA treatment, comes at a maximum retail price of around INR600,000 ($8,067) per bottle...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
